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Abstract
Objective: To evaluate the reliability of a one-week versus a four-week recall period of the
Medical Outcomes Study Sleep Scale (MOS-SS) in patients with fibromyalgia (FM).
Methods: The MOS-SS was administered by mail to patients with a confirmed diagnosis of FM and
a current pain rating of > 2 (0–10 point numerical rating scale) recruited through newspapers,
support groups, and the Internet. Reliability of MOS-SS subscale domains was evaluated using test-
retest methodology separated by a 1–3 day interval for the 4-week recall period and a 7-day
interval for the 1-week recall period. Patient Impression of Change was evaluated for sleep, and for
patients with no change, the intraclass correlation coefficient (ICC) and the Pearson correlation
coefficient was calculated for MOS-SS subscales.
Results: Of 129 patients enrolled, 91.3% were female, mean age was 49.4 ± 11.0 years; self-rated
FM severity was moderate-to-severe in 88.1% of patients. MOS-SS subscale scores were similar for
both recall periods with little variation between test-retest. The 9-item Sleep Problems Index
scores ranged from 57.2 ± 14.5 to 61.9 ± 15.8 across all assessments and demonstrated high
reliability which was similar for the 1-week (ICC 0.81) and 4-week (ICC 0.89) recall periods. For
the other MOS-SS subscales, the 1-week recall period also showed good reliability, which was
consistent for the ICC and Pearson correlation coefficients.
Conclusion: A 1-week recall period is adequately reliable for use of the MOS-SS in studies
evaluating sleep disturbance in patients with FM.
Although the etiology of fibromyalgia (FM) is uncertain,
it is generally diagnosed according to the American Col-
lege of Rheumatology (ACR) criteria, which include
chronic, widespread pain for at least 3 months, and the
presence of 11 out of 18 tender points [1]. It has been esti-
mated that approximately 5 million individuals in the
U.S. have FM, with a higher prevalence among women
(3.4%) than men (0.5%) [2]. In other countries, the prev-
alence of FM has been estimated to range between 0.5%
to 5%, also with a higher prevalence among women [3].
FM is associated with a substantial socioeconomic burden
resulting from excess health resource utilization, reduc-
tions in productivity and quality of life, and a health sta-
tus that is poorer than other chronic pain conditions such
as rheumatoid arthritis and osteoarthritis [4-7]. This bur-
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den is derived not only from the pain, which is character-
istic of FM and is considered the hallmark symptom, but
also from a constellation of other symptoms including
sleep disturbance, which after pain, is a major complaint
of patients with FM and may be an integral component of
the condition. Specific alterations in sleep architecture
have been documented in patients with FM by polysom-
nography [8-10], suggesting an association between sleep
dynamics and the underlying pathophysiology.
There is an overall reciprocal relationship between sleep
disturbance and pain [11-13], with correlation between
these outcomes reported in several rheumatologic condi-
tions including FM [14]. A recent study in patients with
FM suggests sleep disturbance may be predictive of pain
[15]. Not surprisingly, both pain and sleep are considered
core domains essential for evaluation in FM clinical trials
[16].
A variety of sleep instruments are available for evaluating
sleep disturbance and its impact [17], including a new
scale for evaluating restorative sleep (Sleep Quality Assess-
ment; SQA) [18]. A review of sleep assessment instru-
ments for use in chronic pain clinical trials suggested that
while none of the currently available instruments are opti-
mal, the Medical Outcomes Study Sleep Scale (MOS-SS)
[19] may represent the best choice [20]. This recommen-
dation was based on overlap between key sleep constructs
that should be evaluated with the domains that are
assessed by the MOS-SS.
The psychometric properties of the MOS-SS have been
evaluated in patients with a variety of conditions charac-
terized by pain including neuropathic pain [21,22], rest-
less legs syndrome [23], and fibromyalgia [24]. These
studies consistently demonstrated its validity and reliabil-
ity for assessing the key constructs of sleep quality and
quantity, and that it is also sensitive to change, suggesting
its utility in clinical trials. However, it has a recall period
of 4 weeks and responses may consequently be subject to
recall bias, potentially compromising the accuracy of
assessment. Such recall bias provides the basis for recom-
mendations by the FDA against the use of patient-
reported outcomes with long recall periods [25]. There-
fore, the purpose of this study was to evaluate the test-
retest reliability of a one-week recall period of the MOS-SS
compared with the four-week recall period in patients
with FM.
Methods
The MOS-SS was included in a stand-alone, longitudinal
study conducted between May and September 2007
designed to evaluate the psychometric properties of sev-
eral outcomes assessment instruments in patients with
FM. Patients were recruited through newspapers, support
groups, and the Internet, and were compensated for par-
ticipation. Individuals were included if they were ≥ 18
years old and provided a confirmed physician diagnosis
of FM for at least 3 months prior to enrollment; the par-
ticipants' clinicians forwarded written confirmation of the
diagnosis of FM to the study investigators. Individuals
were required to have a current pain rating of > 2 on an
11-point numerical rating scale (NRS) to enable enroll-
ment of individuals with a broad range of pain severity,
since another outcome of this study was validation of cut-
points representing moderate and severe pain as previ-
ously described [26]. It is also likely that use of this rating
resulted in a more representative population than limited
by the score ≥ 4 generally required for inclusion in clinical
trials of FM [27-33]. The ability to read/understand Eng-
lish and cooperate with investigators and study proce-
dures were also required. Exclusion criteria included a
previous diagnosis of rheumatoid arthritis or systemic
lupus erythematosus and/or any other chronic painful
condition that could confound the ability to distinguish
other chronic pain from pain related to FM. Eligible par-
ticipants completed informed consent and study partici-
pation forms; protocol and study documents were
approved by the appropriate Institutional Review Board.
The MOS-SS is a 12-item questionnaire that aims to eval-
uate key constructs of sleep, with derived subscales for the
domains of sleep disturbance (4 items), quantity of sleep
(1 item), snoring (1 item), awakening due to short of
breath or with headache (1 item), sleep adequacy (2
items), and somnolence (3 items) [19]. Additionally, a 9-
item Sleep Problems Index can be generated which
assesses overall sleep problems. It includes the 4 sleep dis-
turbance and the 2 sleep adequacy items, 2 of the somno-
lence items, and awakening short of breath/headache;
higher scores indicate greater sleep impairment, and this
index is often used in clinical trials as an indication of
sleep quality.
The MOS-SS was administered as a mailed questionnaire.
All patients completed both the 4-week and 1-week recall
period versions of the MOS-SS, with the 4-week recall
period questionnaires administered first. The test and
retest of the MOS-SS using the 4-week recall period were
separated by an interval that ranged between 1 and 3 days,
and for the 1-week recall period, the test and retest were
separated by a 7-day interval. At the time of the retest,
patients also evaluated their impression of change in sleep
(Patient Impression of Change; PIC) for the period
between the test and retest. The PIC was adapted from the
Patient Global Impression of Change for the purpose of
this study by specifying a change in sleep due to FM, but
was based upon methodology widely used to assess
degrees of change [34]. As with the PGIC, it is answered
on a 7-point scale of 1 = very much improved; 2 = muchHealth and Quality of Life Outcomes 2009, 7:12 http://www.hqlo.com/content/7/1/12
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improved; 3 = minimally improved; 4 = no change; 5 =
minimally worse; 6 = much worse; 7 = very much worse.
Paired t-tests were used to determine significance of the
difference between test and retest scores. To evaluate test-
retest reliability of the subscales, the intraclass correlation
coefficient (ICC) using Shrout-Fleiss reliability (single-
score statistic) was calculated from paired values for each
recall period [35]. A value greater than the conventionally
accepted threshold of 0.70 was considered an indication
of reliability [36]. Pearson correlation coefficients were
also calculated as confirmation of the reliability estimates.
This assessment for reliability was performed on data
from stable subjects with respect to the PIC, i.e. patients
who reported "no change."
Results
A total of 129 patients with FM were enrolled; 91.3% were
female, and the mean age was 49.4 ± 11.0 years. Self-rated
FM severity was at least moderate in 88.1% of patients,
and 88.3% reported a duration of FM of at least 2 years
since diagnosis. Approximately two-thirds of the patients
(68.3%) reported taking medications for their FM.
The mean test and retest scores for the MOS-SS domains
and the 9-item Sleep Problem Index, along with general
US population norms that were derived in a validation
study using the 4-week recall period [21], are shown in
Figure 1. Scores were similar using the 4-week and 1-week
recall periods, and generally showed little variation
between the test and retest. The only significant differ-
ences between test and retest values were observed for the
domains of Daytime Somnolence (p = 0.0062) and the 9-
item Sleep Problems Index (p = 0.01) for the 4-week recall
period.
All domain scores for the 4-week recall period showed
substantial differences from population norms, indicating
the presence of sleep impairment. Sleep Disturbance and
Daytime Somnolence were the MOS-SS domains which
had the greatest negative impact on sleep quality for both
the 4-week and 1-week recall period. The Sleep Problems
Index scores, which are shown in Table 1, ranged from
57.2 ± 14.5 to 61.9 ± 15.8 across all assessments, and were
more than twice as high as reported for the general popu-
lation norm (25.8) [21], demonstrating substantial sleep
problems in these patients.
Although 60.4% and 56.9% of patients reported no
change in sleep status on the PIC between the test and
retest for the 4-week and 1-week recall periods, respec-
tively, improvement and worsening were both reported
Test and retest scores on the MOS-Sleep Scale for the 4-week and 1-week recall periods Figure 1
Test and retest scores on the MOS-Sleep Scale for the 4-week and 1-week recall periods. General population 
norms for the U.S. population (not adjusted for age and gender), shown as black horizontal bars, are provided for reference 
from Hays et al. [21] only for the 4-week recall period, since population norms have not been established for a 1-week recall 
period. * p = 0.0062 and † p = 0.01 for the difference between test and retest using paired t-tests.
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by patients. For the 4-week recall period, 8.2% of patients
reported improvement and 23.8% reported worse sleep.
Similarly, for the 1-week recall period, 16.5% reported
improved sleep and 26.7% reported worse sleep.
The test-retest reliability of the MOS-SS domains and the
9-item Sleep Problems Index was assessed for the 78
patients (60.4%) and 62 patients (48.1%) who reported
no change on the PIC for the 4-week and 1-week recall
periods, respectively. The ICC and Pearson correlations
for these patients are shown in Table 2. Except for the
Sleep Adequacy domain, the ICC required threshold of
0.70 was exceeded for both recall periods with slightly
higher values for the 4-week period. For the Sleep Ade-
quacy domain, although the ICC did not achieve the
threshold value, the 1-week recall period resulted in a
higher value (0.69) than the 4-week recall period (0.63).
Values of the Pearson correlation coefficient were compa-
rable to the ICC.
Discussion
The MOS-SS is a validated instrument for evaluating the
impact of disease on sleep [19,21]. Its utility has been fur-
ther demonstrated in chronic pain conditions by charac-
terization of clinically important differences in patients
with neuropathic pain [22] and FM [24]. In an effort to
conform to recent recommendations for the use of
patient-reported instruments with short recall periods
[25], we evaluated the reliability of a 1-week recall period.
The data reported here indicate that the MOS-SS produces
comparable results regardless of the use of a 1-week or 4-
week recall period. All domains and the 9-item Sleep
Problems Index demonstrated adequate reliability that
was similar for both recall periods when no change
occurred in the underlying concept (e.g., sleep interfer-
ence). Similar values suggesting high correlation were
obtained for ICC and Pearson coefficients; ICC is consid-
ered a more conservative estimate of association than
Pearson.
A limitation of this study is that these reliability estimates
were based on patients who showed no change in sleep
status between the test and retest. While the MOS-SS in
general is sensitive to treatment effects, further evaluation
of the 1-week recall period may be required under condi-
tions characterized by a change in sleep disturbance (clin-
ical trials and clinical practice). However, it should be
noted that the psychometric evaluation of the MOS-SS in
patients with FM utilized data from two clinical trials, one
with a 4-week recall, and the other with a 1-week recall;
both recall periods showed similar psychometric charac-
teristics and sensitivity to change [24].
The fact that patients were compensated for participation
is another limitation which may have introduced bias,
since it is not known what effect the compensation may
have had on the selection of patients for this study.
Conclusion
The previously demonstrated psychometric soundness of
the MOS Sleep Scale subscales and overall Sleep Problems
Index combined with the current demonstration of the
reliability of a 1-week recall period suggests the appropri-
ateness of this instrument in the evaluation of sleep dis-
Table 1: Test and retest scores for the 9-item Sleep Problems Index of the Medical Outcomes Study Sleep Scale.
Recall period Test (n) Retest (n) Change (n) p
4 weeks 59.01 ± 14.85 (79) 57.23 ± 14.46 (79) -2.0 ± 6.7 (78) 0.01
1 week 61.9 ± 15.8 (62) 59.9 ± 15.2 (62) -2.0 ± 9.5 (62) 0.11
Table 2: Test-retest reliability of the Medical Outcomes Study Sleep Scale. Results are for stable subjects, defined as patients who 
report 'No Change' on Patient Impression of Change sleep question, with non-missing values for both test and retest.
Domain 4-Week Recall 1-Week Recall
n Test-retest p 
value
Intra-class 
correlationa
Pearson 
correlation
n Test-retest p 
value
Intra-class 
correlationa
Pearson 
correlation
Sleep disturbance 78 0.1707 0.93 0.93 62 0.2354 0.76 0.76
Snoring 76 0.4385 0.90 0.90 61 0.0800 0.83 0.83
Awakening short of breath or 
with headache
78 0.7412 0.87 0.87 62 0.6154 0.73 0.73
Sleep adequacy 78 0.2094 0.63 0.64 62 0.3619 0.69 0.69
Daytime somnolence 78 0.0062 0.88 0.89 62 0.1222 0.84 0.84
9-Item Sleep Problems Index 78 0.0100 0.89 0.90 62 0.1088 0.81 0.81
a Calculated using Shrout-Fleiss reliability: single score statistic.Health and Quality of Life Outcomes 2009, 7:12 http://www.hqlo.com/content/7/1/12
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turbance in patients with FM. However, further
corroboration of the reliability of a 1-week recall period in
clinical trials in patients with FM may be warranted.
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